NDA 211970 · Sarepta Theraps INC
Vyondys 53
Golodirsen · Intravenous · Antisense Oligonucleotide
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jun 4, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Dec 12, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
2 Phase 3, 0 recruiting
FAERS reports
488
96 serious, 8 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 13, 2025.
VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53 [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials. VYONDYS 53 is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials. ( 1 )
Mechanism: Golodirsen is designed to bind to exon 53 of dystrophin pre-mRNA resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping. Exon 53 skipping is intended to allow for production of an internally truncated dystrophin protein in patients with genetic mutations that are amenable to exon 53 skipping [see Clinical Studies ( 14 )].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 12, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLetterLabelReview
1 products under this application
- VYONDYS 53 · GOLODIRSEN 100MG/2ML (50MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Golodirsen" as an intervention, any sponsor and status, largest first.
- Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)Pivotal-lookingCompleted
Sarepta Therapeutics, Inc.Industry
NCT02500381 · 228 participants · Start Sep 28, 2016 · Primary completion Nov 12, 2024
Drug: SRP-4045; SRP-4053 and 1 more · For: Duchenne Muscular Dystrophy
Sites: Phoenix, Arizona; Los Angeles, California; San Diego, California · 76 sites in all
- An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular DystrophyPivotal-lookingTerminated
Sarepta Therapeutics, Inc.Industry
NCT03532542 · 171 participants · Start Aug 2, 2018 · Primary completion Jul 26, 2023
Drug: Casimersen; Golodirsen · For: Duchenne Muscular Dystrophy
Sites: Phoenix, Arizona; Los Angeles, California; Palo Alto, California · 50 sites in all
Sarepta Therapeutics, Inc.Industry
NCT02310906 · 39 participants · Start Jan 13, 2015 · Primary completion Mar 25, 2019
Drug: Placebo; SRP-4053 · For: Duchenne Muscular Dystrophy
Sites: Boston, Massachusetts; Paris, France; Rome, Italy · 5 sites in all
Kevin FlaniganAcademic, hospital or other
NCT04179409 · 3 participants · Start Feb 18, 2020 · Primary completion Sep 1, 2021
Drug: Amondys 45; Exondys 51 and 1 more · For: Duchenne Muscular Dystrophy
Sites: Columbus, Ohio
- An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular DystrophyTerminated
Rare Disease Research, LLCAcademic, hospital or other
NCT04708314 · 2 participants · Start Oct 31, 2020 · Primary completion May 13, 2021
Drug: Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53] · For: Duchenne Muscular Dystrophy
Sites: Atlanta, Georgia; Pittsburgh, Pennsylvania
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product dose omission issue135
- no adverse event78
- poor venous access72
- intentional dose omission38
- device issue35
- covid-1923
- malaise22
- pyrexia20
- vomiting17
- illness14
- nausea13
- headache12
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 27 |
| 2021 | 54 |
| 2022 | 91 |
| 2023 | 103 |
| 2024 | 73 |
| 2025 | 73 |
| 2026 | 67 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vyondys-53 (Golodirsen)
2024 spending
$4.2M
Beneficiaries
n/a
34 claims
Per beneficiary
n/a
$802.93 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,649,068 |
| 2021 | $2,653,196 |
| 2022 | $4,166,647 |
| 2023 | $3,493,288 |
| 2024 | $4,233,056 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Increase in Full-Length Dystrophin by Exon Skipping in Duchenne Muscular Dystrophy Patients with Single Exon Duplications: An Open-label Study.
Nicolau S, Malhotra J, Kaler M, et al. · J Neuromuscul Dis 2024 · Clinical Trial, Phase II
- RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.
Yu AM, Choi YH, Tu MJ · Pharmacol Rev 2020 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Migliorati JM, Liu S, Liu A, et al. · Drug Metab Dispos 2022 · Meta-Analysis, Review
- Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy.
Frank DE, Schnell FJ, Akana C, et al. · Neurology 2020 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial.
Servais L, Mercuri E, Straub V, et al. · Nucleic Acid Ther 2022 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future.
oboda A, Dulak J · Pharmacol Rep 2020 · Systematic Review
Sponsor: Sarepta Theraps INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.